Various novel therapeutic interventions are evaluated to overcome hypertrophy and apoptosis associated with diabetic cardiomyopathy. In this study, the anti‐apoptotic and anti‐hypertrophic efficiency of a short peptide composed of Val‐His‐Val‐Val (VHVV) from a soy‐protein hydrolysate was investigated against high glucose (HG) challenge. H9c2 cells were challenges with 33 mM of glucose and showed elevated levels of apoptotic events, pro‐apoptotic proteins, and hypertrophic markers in HG administered H9c2 cells however the abnormalities were efficiently attenuated by VHVV. Further the protective effects of VHVV were further confirmed by administering VHVV on STZ‐induced DM ICR mice. DM ICR mice exhibited notable difference in tissue architecture in liver, heart, and pancreas as determined by Hematoxylin–Eosin staining. Our results conclude that low and high doses of VHVV treatment effectively suppressed the effects of DM in ICR mice by inhibiting the deterioration in gluocgan and insulin secreation in the pancreas indicating enhanced the β‐cell function.
Practical applications
Practical applications
Soy‐protein, isolated from soybean meal, has been consumed for several decades for its functional properties and is also a regular constituent of various food supplements. The functional properties of soy‐protein include its positive effects on serum cholesterol, low‐density lipoprotein cholesterol, and triglyceride levels. Soy‐protein has been demonstrated to possess protection against diabetes associated damages in human. The results of the present study indicate that VHVV, a short peptide derived from soy‐protein hydrolysate is an active anti‐diabetic principle in the soy‐protein. The finding identifies a novel form of antidiabetic peptide that can be used as functional ingredients in food supplements for debates management and health care.